February 2026 in “Preprints.org” Reporter characteristics affect detection of hair loss from cancer therapy.
1 citations
,
January 2024 in “Dermatologic Therapy” Combining tacrolimus with excimer light is more effective for treating alopecia areata than using excimer light alone.
TNFα and interleukin-1 blockers reduce skin inflammation from EGFR antibody therapy.
TNFα and interleukin-1 blockers reduce skin inflammation from EGFR antibody therapy.
June 2008 in “Experimental Dermatology” 17-beta estradiol and prednisolone may help regrow hair damaged by chemotherapy.
13 citations
,
August 1980 in “Cancer” Multimodal primary treatment improves survival in premenopausal breast cancer patients and is also beneficial for postmenopausal women.
2 citations
,
March 2022 in “Modern Rheumatology Case Reports” A medicine called tofacitinib worked to treat a hair loss condition linked with a muscle and skin disease.
April 2022 in “Reactions Weekly” January 2018 in “Refubium (Universitätsbibliothek der Freien Universität Berlin)” Chemotherapy causes temporary hair loss in women, while Tamoxifen does not significantly affect hair, and genetics show no link between female pattern hair loss and common baldness genes.
7 citations
,
January 2023 in “Anti-Cancer Drugs” Early diagnosis and treatment of EGFR inhibitor-induced folliculitis decalvans can prevent permanent hair loss.
1 citations
,
February 2015 in “Clinical and Experimental Dermatology” A man got six skin cancers within a year after a cell transplant for leukemia but was cancer-free 32 months later; skin checks are important post-transplant.
2 citations
,
September 2024 in “Internal Medicine Journal” Upadacitinib helped regrow hair and maintain ulcerative colitis remission.
4 citations
,
April 2016 in “Journal of The American Academy of Dermatology” A patient with advanced kidney cancer and no hepatitis C developed skin inflammation due to a drug called interferon alpha-2a.
July 2024 in “Journal of Investigative Dermatology” Sex and race affect immune responses and treatment outcomes in Hidradenitis suppurativa.
March 2022 in “International Journal of Trichology” Tofacitinib may be effective for treating hair loss caused by alopecia areata that doesn't respond to other treatments.
7 citations
,
October 2024 in “Frontiers in Immunology” A humanized CXCL12 antibody may delay and treat alopecia areata by altering the immune response.
April 2016 in “The journal of investigative dermatology/Journal of investigative dermatology” Combining UVB irradiation and anti-CD154 antibody improves hair follicle transplant survival.
1 citations
,
April 2010 in “Cancer Research” WYE-130600 may cause skin thickening and irritation.
52 citations
,
May 1993 in “Southern Medical Journal” Imuvert can prevent some chemotherapy-induced hair loss.
Tofacitinib and low-dose IL-2 may help maintain hair regrowth in alopecia areata without ongoing treatment.
Dutasteride reduces prostate cancer risk by 23% in high-risk men.
2 citations
,
February 2025 in “Advanced Healthcare Materials” Perhexiline can effectively target ovarian cancer cells left after treatment.
5 citations
,
August 2020 in “Curēus” The document concludes that recent studies help tell apart desmoplastic trichoepitheliomas from other skin tumors, but more research is needed for clear differentiation.
A new 3D breast tumor model helps test drug effects more accurately than traditional methods.
DHEA inhibits growth in both mouse and human melanoma cells but works differently in each.
80 citations
,
June 2000 in “Modern Pathology” Long-standing benign tumors can become cancerous, especially in people with weakened immune systems.
18 citations
,
January 2021 in “Theranostics” The targeted nanohybrids effectively reduced psoriasis symptoms and improved skin health.
September 2004 in “Inpharma Weekly”
2 citations
,
May 2023 in “Cancer medicine” KRT80 may worsen cancer by increasing growth and spread, but its full effects on treatment and outcomes need more research.
Activating certain hair follicle cells could prevent hair loss from cancer treatments.